A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | MicrobiomeTrials← Back to trialsNCT07717411
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-11-30Est. Completion: 2032-09-03
Enrollment target: 1,600 participants Locations- Irvine Center for Clinical Research, Irvine, California, United States
- Syrentis Clinical Research, Santa Ana, California, United States
- K2 Medical Research, LLC, Maitland, Florida, United States
- Basil Clinical, Laurelton, New York, United States
- Toronto Memory Program, Toronto, Ontario, Canada
- Xuanwu Hospital, Capital Medical University, Beijing, China
- Surrey and Borders NHS Foundation Trust, Chertsey, United Kingdom
Other microbiome trials you might be interested in
Cognitive ImpairmentLong-term Care Centres for Old Adults Users
The goal of this clinical trial is to learn if an immersive virtual reality mindfulness meditation program is feasible a…
Québec, CanadaEst. completion Jun 15, 2027
Cognitive Abnormality
The goal of the current study is to evaluate a decision-support tool intended to help primary care providers (PCPs) comm…
Madison, United StatesEst. completion Nov 15, 2027
Recruiting
Alzheimer s DiseaseMild Cognitive ImpairmentHealthy
Background:
About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disea…
Bethesda, United StatesEst. completion Apr 11, 2029